Item 2.02 Results of Operations and Financial Condition.

The information set forth in Item 7.01 is hereby incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure.

On January 9, 2023, ORIC Pharmaceuticals, Inc. (the "Company") issued a press release announcing a corporate update, anticipated milestones for 2023 and the Company's participation in the 41st Annual JP Morgan Healthcare Conference.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 7.01 and Items 2.02 and 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits

Exhibit
  No.        Description

99.1           Press Release dated January 9, 2023

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).



                                      -2-

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses